• FDA cleared Takeda’s ORZEYFUL (oveporexton) for narcolepsy type 1 in adults, marking the first orexin-based therapy targeting the disease’s underlying cause.
• US launch timing hinges on DEA controlled-substance scheduling, expected within 90 days.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608051810BIZWIRE_USPR_____20260805_BW760759) on August 05, 2026, and is solely responsible for the information contained therein.